HLA class II loss and JAK1/2 deficiency coevolve in melanoma leading to CD4 T cell and IFNgamma cross-resistance. Stupia S, Heeke C, Bruggemann A, Zaremba A, et al. Clin Cancer Res 2023 May 18:CCR-23-0099. doi: 10.1158/1078-0432.CCR-23-0099.

Read + Share

Amedeo Smart

Independent Medical Education

Stupia S, Heeke C, Bruggemann A, Zaremba A, et al. HLA class II loss and JAK1/2 deficiency coevolve in melanoma leading to CD4 T cell and IFNgamma cross-resistance. Clin Cancer Res 2023 May 18:CCR-23-0099. doi: 10.1158/1078-0432.CCR-23-0099.
PMID: 37199727